Expertise in
11
conditions

Dr. Antoine Hage

Cardiology
Cedars-Sinai Cardiac Amyloidosis
127 S San Vicente Blvd Ste A6100, 
Los Angeles,, CA 
Expertise in
11
conditions
Cedars-Sinai Cardiac Amyloidosis
127 S San Vicente Blvd Ste A6100, 
Los Angeles,, CA 

Overview

Antoine Hage is a Cardiologist in Los Angeles,, California. Dr. Hage is highly rated in 11 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Mitral Valve Regurgitation, Heart Failure, and Heart Transplant.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Cardiology

Licenses

Internal Medicine in CA

Hospital Affiliations

Cedars-Sinai Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMSA
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Cedars-Sinai Cardiac Amyloidosis
127 S San Vicente Blvd Ste A6100, Los Angeles,, CA 90048
Other Locations
Cedars-Sinai California Heart Center
8670 Wilshire Blvd Fl 2, Beverly Hills,, CA 90211

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

8 Total Publications

Best Practices for Right Heart Catheterization in the Diagnosis of Pulmonary Hypertension.
Best Practices for Right Heart Catheterization in the Diagnosis of Pulmonary Hypertension.
Journal: Chest
Published: March 24, 2025
Similar Doctors
Gregg Fonarow
Expertise in
37
conditions
Dr. Gregg Fonarow
Cardiology
Expertise in
37
conditions
Dr. Gregg Fonarow
Cardiology

Office

100 Medical Plz E Ste 630, 
Los Angeles, CA 
 (3.6 miles away)
310-825-8816
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gregg Fonarow is a Cardiologist in Los Angeles, California. Dr. Fonarow is highly rated in 37 conditions, according to our data. His top areas of expertise are Heart Failure, Heart Attack, Atrial Fibrillation, Thrombectomy, and Percutaneous Coronary Intervention (PCI).

Michelle Kittleson
Expertise in
31
conditions
Dr. Michelle Kittleson
Cardiology
Expertise in
31
conditions
Dr. Michelle Kittleson
Cardiology

Babak Larian Inc.

8670 Wilshire Blvd Ste 200, 
Beverly Hills,, CA 
 (0.1 miles away)
310-248-8300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michelle Kittleson is a Cardiologist in Beverly Hills,, California. Dr. Kittleson is highly rated in 31 conditions, according to our data. Her top areas of expertise are Heart Failure, Cardiomyopathy, Cardiac Amyloidosis, Heart Transplant, and Stent Placement.

Expertise in
38
conditions
Dr. Robert Siegel
Cardiology
Expertise in
38
conditions
Dr. Robert Siegel
Cardiology

Office

127 S San Vicente Blvd Fl 3, 
Los Angeles,, CA 
 (0.7 miles away)
310-423-2726
Languages Spoken:
English
See accepted insurances

Robert Siegel is a Cardiologist in Los Angeles,, California. Dr. Siegel is highly rated in 38 conditions, according to our data. His top areas of expertise are Mitral Valve Regurgitation, Aortic Regurgitation, Atrial Septal Defect (ASD), Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR).

Frequently Asked Questions about Dr. Antoine Hage

How do I make an appointment with Dr. Antoine Hage?

You can book an appointment with Dr. Antoine Hage by calling their office at 310-423-2077. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Antoine Hage a top-rated expert for Pulmonary Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Antoine Hage is classified as an Distinguished expert for Pulmonary Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Antoine Hage specialize in?

While Dr. Antoine Hage is a Cardiology, they have specific expertise in Pulmonary Hypertension, Heart Transplant, and Pulmonary Veno-Occlusive Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Cardiology.

Does Dr. Antoine Hage participate in research or clinical trials?

Yes. Dr. Antoine Hage has published 8 articles and abstracts on conditions like Pulmonary Hypertension. You can view a list of Dr. Antoine Hage's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Antoine Hage accept my insurance?

Dr. Antoine Hage accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 310-423-2077 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hage's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 46 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile